Uncomplicated Staphylococcus aureus Bacteremia Treatment Duration and Outcomes at an Academic Medical Center

被引：3
|
作者：
Taupin, Daniel [1 ]
Karchmer, Adolf W. [1 ]
Davis, Roger B. [2 ]
LaSalvia, Mary T. [1 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA
来源：
OPEN FORUM INFECTIOUS DISEASES | 2020年 / 7卷 / 10期
基金：
美国国家卫生研究院;
关键词：
antibiotic duration; staphylococcal infections; uncomplicated bacteremia; MANAGEMENT; CARE;
D O I：
10.1093/ofid/ofaa457
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We compared outcomes and clinical characteristics of uncomplicated Staphylococcus aureus bacteremia planned for a 14-day or >14-day course of intravenous antibiotics. Treatment failure was infrequent in both groups (0% and 5%, respectively). Catheter-associated deep vein thrombosis, immunosuppression, and valvular dysfunction were associated with a longer planned duration of therapy.
引用
收藏
页码：1 / 4
页数：4
相关论文
共 50 条
  • [31] Long-Term Infectious Complications and Their Relation to Treatment Duration in Catheter-Related Staphylococcus aureus Bacteremia
    M. M. P. Zeylemaker
    C. A. J. J. Jaspers
    M.G.J. van Kraaij
    M. R. Visser
    I. M. Hoepelman
    European Journal of Clinical Microbiology and Infectious Diseases, 2001, 20 : 380 - 384
  • [32] Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia
    Zeylemaker, MMP
    Jaspers, CAJJ
    van Kraaij, MGJ
    Visser, MR
    Hoepelman, IM
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (06) : 380 - 384
  • [33] Impact of Infectious Diseases Consultation on the Treatment of Staphylococcus aureus Bacteremia
    Lewis, Paul O.
    Brewster, Aaryn M.
    Ibrahim, Lamis W.
    Youssef, Dima A.
    Kullab, Susan M.
    Patel, Paras D.
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2020, 28 (02) : 67 - 70
  • [34] Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia
    White, Bryin Pinckney
    Barber, Katie E.
    Stover, Kayla R.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (04) : 201 - 208
  • [35] Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
    Pedro L. Gonzalez
    Urania Rappo
    Karthik Akinapelli
    Jennifer S. McGregor
    Sailaja Puttagunta
    Michael W. Dunne
    Infectious Diseases and Therapy, 2022, 11 : 423 - 434
  • [36] Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA
    Rasmussen, Rasmus V.
    Fowler, Vance G., Jr.
    Skov, Robert
    Bruun, Niels E.
    FUTURE MICROBIOLOGY, 2011, 6 (01) : 43 - 56
  • [37] Evaluation of the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
    Usery, Justin B.
    Vo, Ngan H.
    Finch, Christopher K.
    Cleveland, Kerry O.
    Gelfand, Michael S.
    Self, Timothy H.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2015, 349 (01): : 36 - 41
  • [38] Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
    Gonzalez, Pedro L.
    Rappo, Urania
    Akinapelli, Karthik
    McGregor, Jennifer S.
    Puttagunta, Sailaja
    Dunne, Michael W.
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) : 423 - 434
  • [39] Impact of Management and Bacterial Genomics on Outcomes of Staphylococcus aureus Bacteremia in Children
    Faden, Howard
    Gill, Steven
    Lesse, Alan
    CLINICAL PEDIATRICS, 2011, 50 (10) : 929 - 935
  • [40] Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis
    Kanafani, Z. A.
    Kourany, W. M.
    Fowler, V. G., Jr.
    Levine, D. P.
    Vigliani, G. A.
    Campion, M.
    Katz, D. E.
    Corey, G. R.
    Boucher, H. W.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (12) : 1477 - 1482
12345